Soranib

Sorafenib is pharmacologically categorized as protein kinase inhibitor, which is FDA approved compound used for the treatment of primary renal cell cancer in advanced stage, metastatic liver carcinoma (sorafenib liver cancer) and also involved in radioactive iodine resistant advanced thyroid cancer. Sorafenib is considered as synthetic compound aiming signal responding for growth and angiogenesis. Sorafenib works by blocking the enzyme RAF kinase, which is a demanding component of the RAF/MEK/ERK signaling pathway that dominates cell separation and multiplication. On the other hand, Sorafenib also prohibits the VEGFR-2/PDGFR-beta signaling force, through blockade of tumor angiogenesis.

Sorafenib

Soranib

200mg

Cipla




Soranib (Sorafenib) prescribing information

Sorafenib is available in the form of tablet, which is used in various conditions like;
Metastatic renal cell cancer
Metastatic Hepatocellular cancer
(Sorafenib hepatocellular carcinoma)
Thyroid cancer

Soranib (Sorafenib) mechanism of action

The activity of Soranib containing Sorafenib is developing in-vitro. Soranib expels its activity by prohibiting assorted intracellular & cell surface kinase which is important for tumor cell signaling exudation, angiogenesis and apoptosis.

Due to prohibition of these multikinases is a source of cancer growth termination. Reduction of cancer cell angiogenesis happens in HCC, RCC and elevation of cancer cell apoptosis occurs in HCC, RCC & TC



ADME PROPERTIES

The oral bioavailability of Soranib is occurs as 38 to 49%. The peak plasma concentration time of Soranib is 3 hours.

Sorafenib is highly bound to the human plasma protein at the range of 99.5%

Soranib is undergoes oxidative metabolism, intermediated by CYP3A4, in addition of Glucuronidation mediated by UGT1A9.

The excretion of Soranib occurs via urine, feces and biliary excretion also undergone. Overall 96% of dose should be replaced within 14 days, in which 77% excreted in feces; 19% in urine. The unchanged form of Sorafenib is around 51% should be recovered in feces and not in urine, biliary excretion also occurred. The half-life period of Soranib is relatively 25 to 48 hours.




Blueberrypharma.com

Soranib 200mg
Brand Soranib
Ingredients Sorafenib
Strength 200mg
Manufactured Cipla
Rating


Dosage regimens of Soranib tablets

In HCC, RCC or TC condition: The usual prescribed dosage of Soranib is 400mg tablet (200mg×2 tablets) should be taken as two times a day.

Dosage alteration in severe conditions

Soranib tablets used therapy should be postponed for short period of time in major surgical procedures. Soranib tablets should be postponed or permanently discontinued for following conditions like; Hemorrhage, Cardiac ischemia, Severe hypertension, Gastrointestinal perforation, QTc prolongation, Liver injury

Dose variation in HCC & RCC

The dosage should be varied in HCC & RCC, if dose reduction is required. The dosage should be decreased to 400mg as a single dose. If further reduction is required, provide 400mg as a single dose for alternative day.

Dose variation in dermatological toxicities with HCC

Grade 1 toxicity: Extend the Soranib therapy and provide with topical therapy for symptomatic relief.
Grade 2 toxicity: Extend the Soranib therapy and provide with topical therapy for symptomatic relief. If it occurs continuously, discontinue the Soranib therapy.
Grade 3 toxicity: Discontinue the Soranib therapy, if it is needed the dose should be reduced by two times a day into single dose.

Dose alteration in thyroid carcinoma

First dose reduction: 600mg of Soranib should be recommend
Second dose reduction: 400mg of Soranib should be prescribed for two times a day
Third dose reduction: 200mg of Soranib should be prescribed as a single dose.

In concurrent use of CYP3A4 inducers

Soranib tablets should be co administered with CYP3A4 inducers like anti-convulsants; st.Johns wort etc causes decreasing the systemic exposure of Sorafenib. The efficiency of Sorafenib has not been established in pediatric patients. The Dosage should not be adjusted in elderly patients. In renal and hepatic impairment patients, no dosage adjustment should be recommended. Soranib tablets should be taken without food. Soranib tablets should be taken at least 1 hour earlier or 2 hours after a meal

Soranib tablet causes some adverse effects

Hypertension Myocardial infarction or ischemia Gastrointestinal perforation Drug caused hepatitis Hemorrhage

Most common side effects (Sorafenib)

Diarrhea, Alopecia, Infection, Hand foot skin reaction, Musculoskeletal disorders, Loss of weight, Increasing amylase & lipase

Post marketing adverse effects

Stevens Johnson syndrome, Angioedema, Rhabdomyolysis, Osteonecrosis, Interstitial lung disease, Folliculitis, Leucopenia, Neutropenia, Anemia, Thrombocytopenia, Hypothyroidism, Hypocalcaemia, Hypokalemia, Hyponatremia, Depression, Peripheral sensory neuropathy, Tinnitus, Congestive heart failure, Rhinorrhoea, Dysphonia, Gastro esophageal reflux

Safety measures
Some adverse reactions occur during the treatment with Soranib tablets;

Exposure of GI perforation
Stop the therapy of Soranib tablets.

Warfarin
Combination of Soranib with warfarin causes elevation of INR level. To avoid this problem monitor the patients bleeding (prothrombin time) frequently.

Wound healing complications
Soranib tablets should be postponed during surgical procedures, to prevent wound complications.

Elevation of mortality during combination of Soranibwith carboplatin/paclitaxel and gemcitabine/cisplatin in squamous lung cancer
This combination is contraindicated for the patients with squamous cell lung cancer.

Exposure of QT extension
Soranib causes prolongation of QT intervals; avoid this therapy in patients who have cardiac problems.

Therapy induced hepatitis
During the therapy with Soranib , causes elevation of transaminase leads to liver injury and causes liver failure.

Embryo fetal harm
Soranib tablet causes fetal harm

Thyroid stimulating hormone impairment in thyroid carcinoma
TSH level should be monitored frequently and adjust thyroid replacement.

Exposure of cardiac ischemia or infarction
To avoid this condition, postpone or discontinue the therapy

Exposure of hemorrhage
Permanent discontinuation of Soranib therapy

Exposure of hypertension
Monitor the blood pressure frequently and provide anti-hypertensive agents for this condition.

Other drugs

Soranib tablets while combining with Midazolam, dextromethorphan, or Omeprazole causes no elevation of systemic exposure of these drugs.

Antibiotics

While combining Soranib with antibiotic like neomycin causes depletion AUC of Sorafenib. The solubility of Soranib is depends upon pH, if pH increases causes decreasing the solubility.

Anti-cancer drugs

Combination of Soranib with other anti-neoplastic agents likes; Paclitaxel or carboplatin: Causes elevation of exposure of Sorafenib Capecitabine: Increase Capecitabine exposure Doxorubicin/Irinotecan: Elevation of AUC of doxorubicin and Irinotecan With neomycin: Intercede with enterohepatic recycling of Sorafenib, causes depletion of Sorafenib exposure.

CYP3A4 inducers

Soranib tablets combined with strong CYP3A4 inducers like rifampin causes decrease in AUC of Sorafenib. Avoid concurrent use of Soranib with strong CYP3A4 inducers like anti-convulsants, anti-mycobacterials& herbal product like st.Johns wort. This results as to cause loss of exposure to Sorafenib and leads to reduce the therapeutic effect of Soranib tablets.

CYP3A4 inhibitors

Soranib tablets are combined with strong CYP3A4 inhibitors like ketaconazole causes no variation in AUC of Sorafenib.



In patients with squamous cell lung cancer, are contraindicated in combination of Soranib with carboplatin & paclitaxel. Some anaphylactic reactions occur, if patients are contraindicated to the component of Soranib tablets.

The pregnancy category of Soranib tablet: D Soranib tablets should not be recommended in pregnancy conditions Breast feeding should not be recommended

Soranib tablet stored at 25°C (77°F). Protect the container from moisture, heat and light

Soranib tablet is a chemo drug, used only by the patients having a valid prescription If patients fail to take the dose of Soranib , must consult with medical practitioner and follow the instruction. On the other hand, the missed dose should be skipped and follow the regular dosing schedule.

Blueberrypharma.com-img2



Quick Contact




Prescription upload






PRESCRIPTION


Blueberrypharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Blueberrypharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Blueberrypharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Blueberrypharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Blueberrypharma.com

At Blueberrypharma.com , a Caregiver can order prescription medicines on your behalf.